YM150
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Thromboembolism
Conditions
Thromboembolism
Trial Timeline
Jun 1, 2006 → Aug 1, 2007
NCT ID
NCT00353678About YM150
YM150 is a phase 2 stage product being developed by Astellas Pharma for Thromboembolism. The current trial status is completed. This product is registered under clinical trial identifier NCT00353678. Target conditions include Thromboembolism.
What happened to similar drugs?
6 of 20 similar drugs in Thromboembolism were approved
Approved (6) Terminated (4) Active (12)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01125670 | Phase 1 | Completed |
| NCT01125657 | Phase 1 | Completed |
| NCT01118559 | Phase 1 | Completed |
| NCT00937820 | Phase 3 | Completed |
| NCT00937911 | Phase 3 | Completed |
| NCT00942435 | Phase 3 | Completed |
| NCT01028950 | Phase 3 | Completed |
| NCT01657981 | Phase 1 | Completed |
| NCT00353678 | Phase 2 | Completed |
Competing Products
20 competing products in Thromboembolism